References :
Ablon, J. The nature of stigma and medical conditions. Epilepsy Behav., 3(6S2):2-9, 2002.
Aicardi, J.
Epileptic encephalopathies of early childhood. Curr. Opin. Neurol. Neurosurg., Jun; 5(3):344-8, 1992.
Berg A. T.; Levy, S. R.; Novotny, E. J. and Shinnar,
S. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia, 37(1): 24-30, 1996.
Bronen, R. A.; Fulbright, R. K.; SPENCER D. D. et al.
Refractory epilepsy: comparison of MR imaging, CT, and histopathologic findings in 117 patients. Radiology, 201(1): 97-105, 1996.
Comission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for Epidemiologic Studies on Epilepsy. Epilepsia, 34(4): 592-596, 1993.
Cowan, L. D.; Bodensteiner, J. B.; Leviton, A. and Doherty, L.
Prevalence of the epilepsies in children and adolescents. Epilepsia, 30(1): 94-106, 1989.
Dulac, O. Epileptic encephalopathy. Epilepsia, 42, Suppl 3:23-6, 2001.
Kramer, U.; Nevo, Y.; Neufeld, M. Y.; Fatal, A.; Leitner, Y. and Harel, S. Epidemiology of epilepsy in childhood: a cohort of 440 consecutive patients. Pediatr. Neurol. 18: 46-50, 1998.
Moreira, F. A. and Guimarães, F. S. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. European Journal of Pharmacology, 512, 199, 2005.
Moshé, S. L.
Seizures in the developing brain. Neurology, 43 (Suppl. 5): S3- S7, 1993.
Pedrazzi, J. F. C.; Pereira, A. C. C. I.; Gomes, F. V.; Bel, E. D.
Perfil antipsicótico do canabidiol. Revista da Faculdade de Medicina de Ribeirão Preto e do Hospital das Clínicas da FMRP, 47, 112, 2014.
Teixeira, P.; Li, M. L.
Percepção de estigma na epilepsia. J. epilepsy clin. neurophysiol., 12 (4), 2006.
Zuardi, A. W.; Crippa, J. A.; Hallak, J. E. et al.
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Pharmaceutical Design, 18, 5131, 2021.